Skinvisible (SKVI) Cash from Investing Activities Growth (3y) (2013 - 2023)
Powered by 
Analysis
Skinvisible (SKVI) Cash from Investing Activities Growth (3y) (2013 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.12 Bn | 626.36 Bn | 17.26 Bn | 33.51% |
| 2 | AbbVie | 440.93 Bn | 434.36 Bn | 12.70 Bn | -51.98% |
| 3 | Merck | 364.34 Bn | 357.20 Bn | 12.21 Bn | 21.19% |
| 4 | Novartis Ag | 268.31 Bn | 260.62 Bn | 11.24 Bn | -47.89% |
| 5 | Pfizer | 158.49 Bn | 146.79 Bn | 10.94 Bn | 27.70% |
| 6 | Sanofi | 52.52 Bn | 45.14 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.27 Bn | 44.27 Bn | - | - |
| 8 | Incyte | 25.01 Bn | 20.47 Bn | 1.57 Bn | -91.04% |
| 9 | United Therapeutics | 21.18 Bn | 18.51 Bn | 683.80 Mn | 33.61% |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 26.00% |
| Jun 30, 2023 | 13.90% |
| Mar 31, 2023 | 15.50% |
| Dec 31, 2022 | -26.22% |
| Sep 30, 2020 | -31.26% |
| Dec 31, 2017 | 15.52% |
| Sep 30, 2017 | 31.90% |
| Mar 31, 2015 | 41.37% |
| Dec 31, 2014 | -15.08% |
| Jun 30, 2014 | 76.48% |
| Mar 31, 2014 | 5.14% |
| Dec 31, 2013 | 32.13% |
| Sep 30, 2013 | -332.90% |